Skip to main content

IP Alert: Is a Product-by-Process Limitation a Fig Leaf?

NEWS -
Is a Product-by-Process Limitation a Fig Leaf? By Sarah A. Kagan Patent applicants may claim their product inventions using product-by-process recitations. These can be useful when one has no analysis at hand that permits describing a product with sufficient physical attributes. Yet, for patentability, the physical attributes must be such that the product is novel…

Helen Hill Minsker moderates INTA/USPTO Mini-Seminar on the Coffee Industry in Alexandria, Va.

NEWS -
Helen Hill Minsker moderated a mini-seminar that focused on the coffee industry on Nov. 7 at the U.S. Patent and Trademark Office in Alexandria, Va. Ms. Minsker, a member of the International Trademark Association’s Government Officials Training Committee, was joined by speakers Ato Getachew Mengisitie Alemu, former director general of the Ethiopian IP Office, and Batur Oktay, director and…

IP Alert: Is the Safe Harbor for Divisional Applications Shrinking?

NEWS -
Is the Safe Harbor for Divisional Applications Shrinking? By Sarah A. Kagan In October, the U.S. Court of Appeals for the Federal Circuit heard arguments in a pair of related cases that may add yet another boundary to the safe harbor of §121. One suit was an appeal from an ex parte reexamination in the…

Banner & Witcoff represents firm client NIKE in IPR wins

NEWS -
Banner & Witcoff was recognized by Law360 for successfully representing NIKE, Inc., in inter partes reviews brought by adidas AG against two NIKE patents related to its FLYKNIT technology. Christopher Renk, Michael Harris, and Aaron Bowling represented NIKE in these proceedings. The Patent Trial and Appeal Board concluded that, based on the arguments and evidence the parties presented,…

IP Alert: Federal Circuit Discredits Special Disclosure Rule for Antibodies

NEWS -
Federal Circuit Discredits Special Disclosure Rule for Antibodies By Sarah A. Kagan For decades, patents claiming antibodies have enjoyed a charmed life. Rather than requiring a written description of the antibodies per se, the U.S. Patent and Trademark Office has allowed claims based on a written description of the antigen to which the antibodies bind.…

IP Alert: Divided Infringement and Subject-Matter Eligibility: Are Mixed Diagnostic and Therapeutic Method Claims Viable and Valuable?

NEWS -
Divided Infringement and Subject-Matter Eligibility: Are Mixed Diagnostic and Therapeutic Method Claims Viable and Valuable? By Sarah A. Kagan Until recently, diagnostic assay developers wanting to protect their innovations with patents have faced a Hobson’s choice: claim a treatment step to gain subject-matter eligibility but do so at the risk of creating downstream enforcement problems…

IP Alert: Subject-Matter Eligibility Swallows Infringement Litigation?

NEWS -
Subject-Matter Eligibility Swallows Infringement Litigation? By Lisa M. Hemmendinger and Sarah A. Kagan On October 4, 2017, the U.S. Court of Appeals for the Federal Circuit heard oral arguments in a case that has been running for more than 10 years—Classen Immunotherapies, Inc., v. Elan Pharmaceuticals, Inc. (No. 17-1033). During that time, much has changed…
Contact Banner Witcoff Share on LinkedIn View this page as a pdf Share on Twitter Email this page Print this page